Dubash, Taronish D.
Bardia, Aditya
Chirn, Brian
Reeves, Brittany A.
LiCausi, Joseph A.
Burr, Risa
Wittner, Ben S.
Rai, Sumit
Patel, Hitisha
Bihani, Teeru
Arlt, Heike
Bidard, Francois-Clement
Kaklamani, Virginia G.
Aftimos, Philippe
Cortés, Javier
Scartoni, Simona
Fiascarelli, Alessio
Binaschi, Monica
Habboubi, Nassir
Iafrate, A. John
Toner, Mehmet
Haber, Daniel A.
Maheswaran, Shyamala http://orcid.org/0000-0002-9356-1709
Funding for this research was provided by:
NIH (2RO1CA129933, 2U01EB012493, R01CA260304-01, R01CA255602-02, 2U01EB012493, U01CA214297, R01CA260304-01, R01CA255602-02, 2U01EB012493, U01CA214297, R01CA260304-01, R01CA255602-02)
HHMI
BCRF
NFCR
ESSCO
BCRF
Article History
Received: 22 March 2023
Accepted: 26 May 2023
First Online: 15 June 2023
Declarations
:
: A.B. Consultant/Advisory board: Pfizer, Novartis, Genentech, Merck, Radius Health, Immunomedics/Gilead, Sanofi, Daiichi Pharma/Astra Zeneca, Phillips, Eli Lilly, Foundation Medicine, Contracted Research/Grant (to institution): Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics/Gilead, Daiichi Pharma/Astra Zeneca, Eli Lilly. A.J.I. received royalties from Invitae, and is a SAB member of Oncoclinicas Brasil, SequreDx, Repare Therapeutics and Kinnate Biopharma. H.A., H.P., and T.B. are former employees and shareholders of Radius Health, Inc. F.C.B. Consulting or Advisory Role: Pfizer, AstraZeneca, Lilly, Novartis, Radius Health, Menarini, Sanofi (Inst), Speakers’ Bureau: Pfizer, Novartis, AstraZeneca, Roche, Lilly, Rain Therapeutics, Research Funding: Novartis (Inst), Pfizer (Inst), Menarini Silicon Biosystems (Inst), Prolynx (Inst), Patents, Royalties, Other Intellectual Property: ESR1 & MSI detection techniques (patents; Inst) and Travel, Accommodation Expenses: Roche, Pfizer, AstraZeneca, Novartis. V.G.K. Honoraria: Genentech, Novartis, Pfizer, Genomic Health, Puma Biotechnology, AstraZeneca, Seattle Genetics, daichi, Gilead Sciences, Consulting or Advisory Role: Amgen, Eisai, Puma Biotechnology, Celldex, AstraZeneca, Athenex, bioTheranostics, Speakers’ Bureau: Genentech, Novartis, Genomic Health, Puma Biotechnology, Pfizer, AstraZeneca/Daiichi Sankyo and Research Funding: Eisai. P.A. Honoraria: Synthon, Roche, Gilead Sciences, Consulting or Advisory Role: Macrogenics, Boehringer Ingelheim, Novartis, Amcure, Roche, Novartis, Amgen, Servier, G1 Therapeutics, Radius Health, Deloitte, Menarini, Gilead Sciences and Travel, Accommodations Expenses: Amgen, MSD Oncology, Roche Belgium, Pfizer. J.C. Stock and Other Ownership Interests: MedSIR, Nektar, Leuko, Honoraria: Novartis, Eisai, Celgene, Pfizer, Roche, Samsung, Lilly, Merck Sharp & Dohme, Daiichi Sankyo, Consulting or Advisory Role: Celgene, Cellestia Biotech, AstraZeneca, Roche, Seattle Genetics, Daiichi Sankyo, ERYTECH Pharma, Polyphor, Athenex, Lilly, Servier, Merck Sharp & Dohme, GlaxoSmithKline, Leuko, Clovis Oncology, Bioasis, Boehringer Ingelheim, Ellipses Pharma, HiberCell, Bioinvent, GEMoaB, Gilead Sciences, Menarini, Zymeworks, Reveal Genomics, Research Funding: ARIAD (Inst), Astrazeneca (Inst), Baxalta (Inst), Bayer (Inst), Eisai (Inst), Guardant Health (Inst), Merck Sharp & Dohme (Inst), Pfizer (Inst), Puma Biotechnology (Inst), Queen Mary university of London (Inst), Roche (Inst), Piqur (Inst), Patents, Royalties, Other Intellectual Property: Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A, Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy. Aleix Prat, Antonio Llombart, Javier Cortés. US 2019/ 0338368 A1 and Travel, Accommodations Expenses: Roche, Pfizer, Eisai, Novartis, Daiichi Sankyo, Gilead Sciences. S.S., A.F., M.B., and N.H. are employees of Menarini Ricerche. M.T., D.A.H., and S.M. are founders of and own equity in TellBio, Inc., which is involved with CTC diagnostics and therapeutics. No funding was received from TellBio, Inc. for this work. No disclosures were reported by the other authors.
: Patients provided written informed consent to an Institutional Review Board approved blood collection protocol (DF/HCC 05–300).